Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin-or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells
Autore:
Zhang, LL; Wan, XS; Donahue, JJ; Ware, JH; Kennedy, AR;
Indirizzi:
Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 iat Oncol, Philadelphia, PA 19104 USA
Titolo Testata:
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
fascicolo: 2, volume: 33, anno: 1999,
pagine: 165 - 173
SICI:
0163-5581(1999)33:2<165:EOTBIO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
OVARIAN-CARCINOMA CELLS; HUMAN-TUMOR CELLS; C-MYC EXPRESSION; PROTEASE INHIBITOR; LUNG-CANCER; DNA-REPAIR; CROSS-RESISTANCE; IN-VITRO; LINE; MECHANISMS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
70
Recensione:
Indirizzi per estratti:
Indirizzo: Wan, XS Univiladelphia,Med, Dept Radiat Oncol, 530 Clin Res Bldg,415 CurieBlvd, Ph Univ Penn 530 Clin Res Bldg,415 Curie Blvd Philadelphia PA USA 19104
Citazione:
L.L. Zhang et al., "Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin-or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells", NUTR CANCER, 33(2), 1999, pp. 165-173

Abstract

Bowman-Birk inhibitor (BBI) is a soybean-derived anticarcinogenic proteaseinhibitor previously shown to potentiate cisplatin-induced cytoxicity in human lung and ovarian cancer cells. To further assess the potential of BBI as a sensitizing agent for cancer radiotherapy and chemotherapy, we evaluated the effects of BBI and a soybean concentrate enriched in BBI known as BBI concentrate (BBIC) on clonogenic survival and radiation- or cisplatin-induced cell killing in MCF7 human breast carcinoma cells, SCC61 and SQ20B human head and neck carcinoma cells, HeLa, HeLa-R1, and HeLa-R3 human cervicalcarcinoma cells, MCF10 nontumorigenic human epithelial cells, HTori-3 nontumorigenic human thyroid epithelial cells, and C3H10T1/2 mouse fibroblast cells. BBI and BBIC significantly sup pressed the clonogenic survival of MCF7 and SCC61 cells. BBIC also suppressed the survival of SQ20B cells and enhanced radiation-induced cell killing in SCC61 and SQ20B cells and cisplatin-induced cell killing in HeLa, HeLa-R1, and HeLa-R3 cells. In contrast, BBIand/or BBIC did not enhance radiation-induced cell killing in MCF10 cells or cisplatin-induced cell killing in C3H10T1/2 cells. BBI did nor significantly affect the survival of SQ20B cells or enhance radiation-induced cell killing in SCC61 and SQ20B cells. The clonogenic survivals of MCF10 and C3H10T1/2 cells were not adversely affected by treatment with BBI or BBIC. The clonogenic survival of HTori-3 cells was only moderately suppressed by treatment with BBIC at greater than or equal to 80 mu g/ml. These results suggest that BBIC could be a useful agent for the potentiation of radiation- andcisplatin-mediated cancer treatment without significant adverse effects onsurrounding normal tissues.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 01:29:38